Emerging Shadow Markets in CGT: Can You Protect Your Patients From Unproven Therapies?
Thursday, May 30, 2024 03:45 PM - 04:45 PM
Room 208-209
Roundtable
Moderator
Identify emerging trends in the marketing of unproven products and tactics employed by bad actors to circumvent regulation.
Key Learning Objectives
1. Build awareness among the community of the emerging trends in the marketing of evidence-poor nominal cell therapies outlined above.
2. Familiarize attendees with concomitant ethical issues, scientific concerns, and regulatory challenges. 3. Prompt critical reflection on potential ways to address issues addressed in this session from an ethical perspective and in terms of institutional policies.
- John Rasko, Prof., Royal Prince Alfred Hospital, Australia
- Douglas Sipp, BA, RIKEN Center for Biosystems Dynamics Research, Japan
- Kirstin R.W. Matthews, PhD, Rice University’s Baker Institute for Public Policy, United States
- Laertis Ikonomou, PhD, University at Buffalo, United States
- Leigh Turner, PhD, University of California, United States
Identify emerging trends in the marketing of unproven products and tactics employed by bad actors to circumvent regulation.
Key Learning Objectives
1. Build awareness among the community of the emerging trends in the marketing of evidence-poor nominal cell therapies outlined above.
2. Familiarize attendees with concomitant ethical issues, scientific concerns, and regulatory challenges. 3. Prompt critical reflection on potential ways to address issues addressed in this session from an ethical perspective and in terms of institutional policies.
Laertis Ikonomou
Associate Professor
University at Buffalo, The State University of New York
Panelist
Associate Professor
University at Buffalo, The State University of New York
Panelist